Displaying 1 - 50 of 105 results
Released Company Title Industry Topic
22 Feb 2024
07:00 CET
ARGENX SE argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024 20103010 Biotechnology Other subject
20 Feb 2024
07:00 CET
ARGENX SE argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy 20103010 Biotechnology Other subject
18 Jan 2024
07:00 CET
ARGENX SE argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis 20103010 Biotechnology Other subject
08 Jan 2024
07:00 CET
ARGENX SE argenx Highlights 2024 Strategic Priorities 20103010 Biotechnology Other subject
02 Jan 2024
07:00 CET
ARGENX SE argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference 20103010 Biotechnology Other subject
20 Dec 2023
07:00 CET
ARGENX SE argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus 20103010 Biotechnology Other subject
28 Nov 2023
07:00 CET
ARGENX SE argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia 20103010 Biotechnology Other subject
16 Nov 2023
13:40 CET
ARGENX SE argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis 20103010 Biotechnology Other subject
01 Nov 2023
07:00 CET
ARGENX SE argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions 20103010 Biotechnology Other subject
01 Nov 2023
07:00 CET
ARGENX SE argenx to Present at Upcoming Investor Conferences 20103010 Biotechnology Other subject
31 Oct 2023
07:00 CET
ARGENX SE argenx Reports Third Quarter 2023 Financial Results and Provides Business Update 20103010 Biotechnology Other subject
24 Oct 2023
07:00 CEST
ARGENX SE argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023 20103010 Biotechnology Other subject
21 Sep 2023
07:00 CEST
ARGENX SE argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis 20103010 Biotechnology Other subject
15 Sep 2023
07:00 CEST
ARGENX SE argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis 20103010 Biotechnology Other subject
30 Aug 2023
07:00 CEST
ARGENX SE argenx to Present at Upcoming Investor Conferences 20103010 Biotechnology Other subject
27 Jul 2023
07:00 CEST
ARGENX SE argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update 20103010 Biotechnology Other subject
24 Jul 2023
22:30 CEST
ARGENX SE argenx announces closing of global offering 20103010 Biotechnology Other subject
20 Jul 2023
07:00 CEST
ARGENX SE argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023 20103010 Biotechnology Other subject
19 Jul 2023
23:58 CEST
ARGENX SE argenx announces full exercise of underwriters’ option to purchase additional ADSs 20103010 Biotechnology Other subject
19 Jul 2023
03:30 CEST
ARGENX SE argenx raises $1.1 billion in gross proceeds in a global offering 20103010 Biotechnology Other subject
17 Jul 2023
22:01 CEST
ARGENX SE argenx announces launch of proposed global offering 20103010 Biotechnology Other subject
17 Jul 2023
07:00 CEST
ARGENX SE argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy 20103010 Biotechnology Other subject
30 Jun 2023
15:39 CEST
ARGENX SE argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China 20103010 Biotechnology Other subject
21 Jun 2023
00:12 CEST
ARGENX SE argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis 20103010 Biotechnology Other subject
20 Jun 2023
07:00 CEST
ARGENX SE argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy 20103010 Biotechnology Other subject
31 May 2023
07:00 CEST
ARGENX SE argenx to Present at Upcoming Investor Conferences 20103010 Biotechnology Other subject
04 May 2023
07:00 CEST
ARGENX SE argenx Reports First Quarter 2023 Financial Results and Provides Business Update 20103010 Biotechnology Other subject
03 May 2023
22:01 CEST
ARGENX SE argenx announces results of Annual General Meeting of Shareholders 20103010 Biotechnology Other subject
02 May 2023
07:00 CEST
ARGENX SE argenx to Present at BofA Securities 2023 Health Care Conference 20103010 Biotechnology Other subject
27 Apr 2023
07:00 CEST
ARGENX SE argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023 20103010 Biotechnology Other subject
18 Apr 2023
07:00 CEST
ARGENX SE argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting 20103010 Biotechnology Other subject
17 Apr 2023
08:00 CEST
ARGENX SE argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology 20103010 Biotechnology Other subject
17 Mar 2023
21:01 CET
ARGENX SE argenx Announces Annual General Meeting of Shareholders on May 2, 2023 20103010 Biotechnology Other subject
15 Mar 2023
14:25 CET
ARGENX SE argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis 20103010 Biotechnology Other subject
02 Mar 2023
07:00 CET
ARGENX SE argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update 20103010 Biotechnology Other subject
02 Mar 2023
07:00 CET
ARGENX SE argenx Announces Planned Transition of Chief Operating Officer 20103010 Biotechnology Other subject
27 Feb 2023
22:01 CET
ARGENX SE argenx Appoints Steve Krognes to Board of Directors 20103010 Biotechnology Other subject
27 Feb 2023
07:00 CET
ARGENX SE argenx to Present at Upcoming Investor Conferences 20103010 Biotechnology Other subject
23 Feb 2023
07:00 CET
ARGENX SE argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023 20103010 Biotechnology Other subject
27 Jan 2023
07:00 CET
ARGENX SE argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod 20103010 Biotechnology Other subject
16 Jan 2023
19:30 CET
ARGENX SE argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director 20103010 Biotechnology Other subject
09 Jan 2023
07:00 CET
ARGENX SE argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline 20103010 Biotechnology Other subject
03 Jan 2023
07:00 CET
ARGENX SE argenx to Present at 41st Annual J.P. Morgan Healthcare Conference 20103010 Biotechnology Other subject
12 Dec 2022
22:01 CET
ARGENX SE argenx Appoints Ana Cespedes to Board of Directors 20103010 Biotechnology Other subject
10 Dec 2022
17:30 CET
ARGENX SE argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia 20103010 Biotechnology Other subject
30 Nov 2022
07:00 CET
ARGENX SE argenx Enters Into Agreement To Acquire Priority Review Voucher 20103010 Biotechnology Other subject
22 Nov 2022
07:00 CET
ARGENX SE argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review 20103010 Biotechnology Other subject
07 Nov 2022
07:00 CET
ARGENX SE argenx to Present at Upcoming Investor Conferences 20103010 Biotechnology Other subject
27 Oct 2022
07:00 CEST
ARGENX SE argenx Reports Third Quarter 2022 Financial Results and Provides Business Update 20103010 Biotechnology Other subject
20 Oct 2022
07:00 CEST
ARGENX SE argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022 20103010 Biotechnology Other subject